Risk of osteoporosis subsequent to chemotherapy for early-stage breast cancer

Carina Ørts Christensen, T. Frøslev, D. Cronin Fenton, P. Hermann, M. Ewertz

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Abstract

Introduction: Breast cancer chemotherapy can increase the risk of osteoporosis. Bone loss may be associated with supportive care medication such as cortico-steroids which are the most common cause of secondary osteoporosis with a 7-17 fold increased risk of fractures with daily doses of 10 mg for 3 months. Objectives: We conducted a prospective cohort study to evaluate the effect of adjuvant chemotherapy on bone mineral density (BMD) as a marker of osteoporosis. Methods: Dual-imaging X-ray absorptiometry (DXA) was performed before chemotherapy (baseline) and after completing chemotherapy (4 months later) to measure spine, hip and forearm BMD among 105 breast cancer patients. During standard adjuvant chemotherapy the patients received up to 1425 mg of prednisolone in intervals as required. Patients were advised to take calcium and Vitamin D daily. We correlated the cumulative dose of prednisolone with the percentage change in BMD using Fishers exact tests. Results: Baseline characteristic is shown in table 1. Ten patients were excluded due to osteoporosis at baseline DXA and one due to poor quality scan. None had osteoporosis at the 2nd DXA. Table 2 shows BMD changes from the 94 patients. Median prednisolone dose was 1305 mg with 90 % receiving at least 1100 mg. Overall, cumulative prednisolone dose was not significantly associated with changes in spine, hip and radius BMD (P>0.05). Conclusions: During chemotherapy bone loss by all three DXA measurements was not detected in any patient and no significant association was found to dose of prednisolone. However, we keep following the patients with DXA.
Original languageEnglish
Article number01-03-O
JournalSupportive Care in Cancer
Volume23
Issue numberSUPPL. 1
Pages (from-to)S32-S33
ISSN0941-4355
DOIs
Publication statusPublished - 2015
EventMASCC/ISOO International Symposium - Bella Center, Copenhagen, Denmark
Duration: 25. Jun 201527. Jun 2015

Seminar

SeminarMASCC/ISOO International Symposium
LocationBella Center
CountryDenmark
CityCopenhagen
Period25/06/201527/06/2015

Cite this

@article{5b33e53c84f649f9883411203d276ec2,
title = "Risk of osteoporosis subsequent to chemotherapy for early-stage breast cancer",
abstract = "Introduction: Breast cancer chemotherapy can increase the risk of osteoporosis. Bone loss may be associated with supportive care medication such as cortico-steroids which are the most common cause of secondary osteoporosis with a 7-17 fold increased risk of fractures with daily doses of 10 mg for 3 months. Objectives: We conducted a prospective cohort study to evaluate the effect of adjuvant chemotherapy on bone mineral density (BMD) as a marker of osteoporosis. Methods: Dual-imaging X-ray absorptiometry (DXA) was performed before chemotherapy (baseline) and after completing chemotherapy (4 months later) to measure spine, hip and forearm BMD among 105 breast cancer patients. During standard adjuvant chemotherapy the patients received up to 1425 mg of prednisolone in intervals as required. Patients were advised to take calcium and Vitamin D daily. We correlated the cumulative dose of prednisolone with the percentage change in BMD using Fishers exact tests. Results: Baseline characteristic is shown in table 1. Ten patients were excluded due to osteoporosis at baseline DXA and one due to poor quality scan. None had osteoporosis at the 2nd DXA. Table 2 shows BMD changes from the 94 patients. Median prednisolone dose was 1305 mg with 90 {\%} receiving at least 1100 mg. Overall, cumulative prednisolone dose was not significantly associated with changes in spine, hip and radius BMD (P>0.05). Conclusions: During chemotherapy bone loss by all three DXA measurements was not detected in any patient and no significant association was found to dose of prednisolone. However, we keep following the patients with DXA.",
keywords = "*osteoporosis *chemotherapy *breast cancer *neoplasm *risk human patient osteolysis hip spine adjuvant chemotherapy secondary osteoporosis radius bone density Fisher exact test cohort analysis drug therapy fracture cancer patient forearm absorptiometry X ray imaging cancer chemotherapy prednisolone corticosteroid marker calcium vitamin D",
author = "Christensen, {Carina {\O}rts} and T. Fr{\o}slev and {Cronin Fenton}, D. and P. Hermann and M. Ewertz",
year = "2015",
doi = "10.1007/s00520-015-2712-y",
language = "English",
volume = "23",
pages = "S32--S33",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Heinemann",
number = "SUPPL. 1",

}

Risk of osteoporosis subsequent to chemotherapy for early-stage breast cancer. / Christensen, Carina Ørts ; Frøslev, T.; Cronin Fenton, D.; Hermann, P.; Ewertz, M.

In: Supportive Care in Cancer, Vol. 23, No. SUPPL. 1, 01-03-O, 2015, p. S32-S33.

Research output: Contribution to journalConference abstract in journalResearchpeer-review

TY - ABST

T1 - Risk of osteoporosis subsequent to chemotherapy for early-stage breast cancer

AU - Christensen, Carina Ørts

AU - Frøslev, T.

AU - Cronin Fenton, D.

AU - Hermann, P.

AU - Ewertz, M.

PY - 2015

Y1 - 2015

N2 - Introduction: Breast cancer chemotherapy can increase the risk of osteoporosis. Bone loss may be associated with supportive care medication such as cortico-steroids which are the most common cause of secondary osteoporosis with a 7-17 fold increased risk of fractures with daily doses of 10 mg for 3 months. Objectives: We conducted a prospective cohort study to evaluate the effect of adjuvant chemotherapy on bone mineral density (BMD) as a marker of osteoporosis. Methods: Dual-imaging X-ray absorptiometry (DXA) was performed before chemotherapy (baseline) and after completing chemotherapy (4 months later) to measure spine, hip and forearm BMD among 105 breast cancer patients. During standard adjuvant chemotherapy the patients received up to 1425 mg of prednisolone in intervals as required. Patients were advised to take calcium and Vitamin D daily. We correlated the cumulative dose of prednisolone with the percentage change in BMD using Fishers exact tests. Results: Baseline characteristic is shown in table 1. Ten patients were excluded due to osteoporosis at baseline DXA and one due to poor quality scan. None had osteoporosis at the 2nd DXA. Table 2 shows BMD changes from the 94 patients. Median prednisolone dose was 1305 mg with 90 % receiving at least 1100 mg. Overall, cumulative prednisolone dose was not significantly associated with changes in spine, hip and radius BMD (P>0.05). Conclusions: During chemotherapy bone loss by all three DXA measurements was not detected in any patient and no significant association was found to dose of prednisolone. However, we keep following the patients with DXA.

AB - Introduction: Breast cancer chemotherapy can increase the risk of osteoporosis. Bone loss may be associated with supportive care medication such as cortico-steroids which are the most common cause of secondary osteoporosis with a 7-17 fold increased risk of fractures with daily doses of 10 mg for 3 months. Objectives: We conducted a prospective cohort study to evaluate the effect of adjuvant chemotherapy on bone mineral density (BMD) as a marker of osteoporosis. Methods: Dual-imaging X-ray absorptiometry (DXA) was performed before chemotherapy (baseline) and after completing chemotherapy (4 months later) to measure spine, hip and forearm BMD among 105 breast cancer patients. During standard adjuvant chemotherapy the patients received up to 1425 mg of prednisolone in intervals as required. Patients were advised to take calcium and Vitamin D daily. We correlated the cumulative dose of prednisolone with the percentage change in BMD using Fishers exact tests. Results: Baseline characteristic is shown in table 1. Ten patients were excluded due to osteoporosis at baseline DXA and one due to poor quality scan. None had osteoporosis at the 2nd DXA. Table 2 shows BMD changes from the 94 patients. Median prednisolone dose was 1305 mg with 90 % receiving at least 1100 mg. Overall, cumulative prednisolone dose was not significantly associated with changes in spine, hip and radius BMD (P>0.05). Conclusions: During chemotherapy bone loss by all three DXA measurements was not detected in any patient and no significant association was found to dose of prednisolone. However, we keep following the patients with DXA.

KW - osteoporosis chemotherapy breast cancer neoplasm risk human patient osteolysis hip spine adjuvant chemotherapy secondary osteoporosis radius bone density Fisher exact test cohort analysis drug therapy fracture cancer patient forearm absorptiometry X ray i

U2 - 10.1007/s00520-015-2712-y

DO - 10.1007/s00520-015-2712-y

M3 - Conference abstract in journal

VL - 23

SP - S32-S33

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - SUPPL. 1

M1 - 01-03-O

ER -